GP practices in the UK will begin prescribing Mounjaro, a medication for type 2 diabetes, to targeted patient groups from late June. This decision was made after a thorough evaluation of the medication's benefits and potential risks, as per National Institute for Health and Care Excellence (NICE) guidelines.
According to Pulse Today, the 'prioritised' patient cohorts will include those with a body mass index (BMI) of 30 or higher, those with co-existing health conditions such as high blood pressure or kidney disease, and patients who have not responded to other treatments.
The NHS has been working to improve treatment options for patients with type 2 diabetes, with a focus on personalised care and managing related health conditions. Mounjaro has been shown to be effective in reducing blood sugar levels and has a lower risk of hypoglycaemia compared to other diabetes medications.
It is essential for patients to consult their GP or call NHS 111 for advice on whether Mounjaro is suitable for them. GPs will assess individual patients' needs and health status before prescribing the medication.
The UK's health service aims to improve patient outcomes and quality of life through targeted treatment approaches. However, the prescription of Mounjaro will be limited to priority patient groups, and other treatment options will remain available for those who do not meet the criteria.